Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of CM529D1 in advanced solid tumors
CTR20263960Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM529D1 in Nonhematologic neoplasms, neuroendocrine carcinoma (NEC), sponsored by Keymed Biosciences. Started Oct 2026; status: active.
02
Drugs
CM529D1
03
Conditions
Nonhematologic neoplasmsneuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20263960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263960.